Pulnovo Medical

What Pulnovo Medical does

Pulnovo Medical is a privately held medical device company founded in 2013 that develops and commercializes the Pulmonary Artery Denervation (PADN) catheter-based ablation system, a minimally invasive interventional therapy for pulmonary hypertension (PH) and heart failure. The PADN procedure delivers targeted radiofrequency ablation to the pulmonary artery to denervate overactive sympathetic nerves, reducing pulmonary arterial pressure and improving cardiac function. The company's clinical and commercial focus spans Group 1 Pulmonary Arterial Hypertension (PAH) and Group 2 combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease, with customers being interventional cardiologists, pulmonary hypertension specialists, and the tertiary hospitals and cardiac centers where they practice.

The PADN system has been used in approximately 1,500 procedures across 150+ global clinical centers, has secured regulatory approvals in seven countries, and has received seven FDA designations including FDA Breakthrough Device Designation. The company pursues a dual-track regulatory and commercialization strategy: direct hospital sales in approved markets (Europe, Asia, Middle East including Saudi Arabia) alongside FDA IDE-driven US clinical trials for both Group 1 and Group 2 indications. In April 2026, Pulnovo entered a strategic commercial agreement with Medtronic alongside a $100M Medtronic-led financing, granting Medtronic rights to leverage its global commercialization infrastructure for the PADN system.

Pulnovo generates revenue through hardware sales of its PADN catheter ablation system to hospitals and clinical centers; device pricing is not publicly disclosed and is set via hospital procurement and regional distribution arrangements. The company is incorporated with operating presence in Shanghai (founding location) and New York (US headquarters), employs 101–250 people, is led by CEO Jessie Lian Jia and Chairman Cynthia Chen, and is backed by a syndicate of international life-sciences investors including Medtronic, EQT, Qiming Venture Partners, OrbiMed, Lilly Asia Ventures, Gaorong Ventures, YuanBio, and HSG.

Name

Pulnovo Medical

Legal name

Pulnovo Medical

Website

https://pulnovomed.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Pulnovo Medical is a privately held medical device company developing the Pulmonary Artery Denervation (PADN) catheter ablation system, a minimally invasive interventional therapy for pulmonary hypertension and heart failure, serving interventional cardiologists, PH specialists, and the tertiary hospitals where they practice across Europe, the Middle East, Asia, and ongoing US IDE trials.

Ownership category

akta.pro rank

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Medical Device Sales: The company generates revenue through the sale of its PADN catheter ablation system and related medical devices. The system is used in hospitals and clinical settings for pulmonary artery denervation procedures to treat pulmonary hypertension and heart failure patients.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

No source content was provided describing the company's core offerings.

Product overview

Pulnovo Medical offers the Pulmonary Artery Denervation (PADN) System as its core medical device product. PADN is a catheter-based intervention that treats pulmonary hypertension through targeted denervation of the pulmonary artery. The company operates as a single-product-focused medical technology firm, with the PADN technology platform serving as the unified offering across multiple markets and clinical applications. The company has achieved 7 regional regulatory approvals, conducted over 1,500 patient procedures globally across 150+ clinical centers, and maintains 7 FDA designations supporting ongoing clinical development for both Group 1 and Group 2 pulmonary hypertension indications.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Approximately 1,500 PADN procedures completed globally across clinical centers
• +2 more outcomes

Named customers1 record

Segments3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• MedtroniccoreGTM or Marketing Partner · 20 April 2026

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Merit Medical Systems: Established interventional cardiology and vascular device manufacturer; comparable in catheter-based product economics, hospital procurement cycles, and global regulatory pathway.
• Medtronic: Global medtech leader in interventional cardiology, cardiac ablation, and catheter-based therapies; Pulnovo's strategic investor and commercialization partner with deep overlap in catheter ablation technology and hospital call points.
• Boston Scientific: Major interventional cardiology and structural heart device company with extensive catheter-based ablation and cardiology portfolios; directly comparable in operating model, regulatory pathway, and hospital customer base.
• Edwards Lifesciences: Heart-focused medtech leader with growing heart failure and structural heart therapy portfolio; highly comparable strategic positioning in addressing advanced cardiovascular disease with novel interventional technologies.
• Abbott: Diversified cardiovascular device incumbent with strong interventional cardiology and heart failure franchises; comparable in regulatory complexity, GTM, and target hospital specialty physicians.
• Johnson & Johnson (Biosense Webster): World leader in electrophysiology catheter ablation; competes in the same hospital cardiology channels and shares the catheter-based ablation technology archetype that Pulnovo uses for PADN.

Emerging players

• AngioDynamics: Vascular and catheter-based therapy company with overlapping hospital call points and product development pipeline in interventional procedures for cardiovascular indications.
• SoniVie: Clinical-stage company developing ultrasound-based renal denervation; comparable as a fellow emerging player in catheter-based denervation therapies pursuing vascular sympathetic modulation.

Regional players

• Venus Medtech: Leading China-based interventional cardiology/structural heart device company; comparable as a Chinese-origin interventional cardiovascular player pursuing global commercialization of novel catheter-based therapies.

Direct peers

• Recor Medical: Pioneer in catheter-based denervation (renal denervation for hypertension); closest direct analog to PADN as a novel neuromodulation/catheter ablation therapy targeting a vascular sympathetic indication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/pulnovo_medical
• LinkedInlinkedin.com/company/pulnovo-medical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pulnovo Medical